ISDS Case Map
health
The India–New Zealand Free Trade Agreement (FTA), signed in April 2026, grants 100% duty-free access for over 8,200 Indian export lines and includes a USD 20 billion investment commitment to Indian pharmaceuticals, medical devices, and engineering exports.
The 2026 NTE Report makes it clear that the Trump administration’s primary motivation behind its trade policy is to protect the profits of big US companies.
A pharma row between Switzerland and the U.K. risks derailing trade talks, with British officials concerned Swiss demands could push up NHS bills.
Alberta’s promised two-tier transition comes with unacknowledged threats from trade and investment agreements.
A study tracks how the North American Free Trade Agreement and trade competition with Mexico led to earlier deaths for American factory workers.
The US-Argentina deal represents a new low in using US trade policy to bully countries into adopting intellectual property rules that expand Big Pharma’s monopoly power at the expense of access to affordable medicines.
The EU-India FTA promises cheaper drugs and medical devices, but India's regulatory framework may hinder patient benefits. Current pricing mechanisms, including market-based ceiling prices and loopholes for fixed-dose combinations, prevent cost reductions from reflecting in retail prices. An urgent overhaul of drug pricing and an independent regulator for procedures are needed to ensure affordability and realize the FTA's full potential.
The Working Group points out that the European Commission's press release states the agreement provides for a high level of protection and enforcement of Intellectual Property rights, including copyright, trademarks, designs, trade secrets and plant variety rights.
The administration said it would pursue similar deals with other countries that have not yet locked in trade agreements with the US to correct a longstanding gripe Trump has had with wealthy European nations that he says pay too little for medicines.
The United States announced a deal with Britain for zero tariffs on pharmaceutical products and medical technology which will lead to Britain spending more on medicines.
